Physician profile
Spencer E Johnson
NPI 1528570116
$7,572.13
in general payments reported to CMS, 2019-2025
25 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $501 · 2022: $1,207 · 2023: $1,157 · 2024: $2,548 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,864.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,087.58 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,172.01 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $710.38 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.95 | 2021-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $551.87 | 2022-2025 | Dupixent |
| Genzyme Corporation | $464.27 | 2022-2025 | |
| Ardelyx, INC. | $370.95 | 2023-2025 | Ibsrela |
| Pfizer INC. | $354.58 | 2023-2025 | |
| Qol Medical, LLC | $209.47 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $130.88 | 2024-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $130.67 | 2021-2024 | Ocaliva |
| Glaxosmithkline, LLC. | $110.97 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $94.80 | 2024-2025 | Zerbaxa, Dificid |
| Ironwood Pharmaceuticals, INC | $78.91 | 2022-2024 | Linzess |
| Celltrion USA INC. | $78.47 | 2025 | Vegzelma |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $74.75 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.16 | 2021-2025 | Ofev, Cyltezo |
| Celgene Corporation | $59.75 | 2022 | |
| Mallinckrodt Hospital Products INC. | $49.69 | 2025 | Acthar |
| Aimmune Therapeutics, INC. | $45.44 | 2025 | Zenpep |
| Grifols USA, LLC | $34.25 | 2024 | Xembify, Prolastin-C Liquid |
| Braintree Laboratories, INC. | $25.69 | 2022 | |
| Electromed, INC. | $23.15 | 2024 | Smartvest |
| Csl Behring | $21.97 | 2023 | Hizentra |
| Alk-Abello, INC | $19.52 | 2025 | Ragwitek, Odactra, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.